Quantcast

Latest Microvesicles Stories

2014-06-03 08:32:14

NEW YORK, June 3, 2014 /PRNewswire/ -- Exosome Diagnostics, a leading developer of non-invasive, biofluid-based molecular diagnostics, today announced that Vincent J. O'Neill, M.D., has been appointed as its chief medical officer. Dr. O'Neill has extensive experience in clinical trial design, regulatory issues, and personalized medicine, most recently as global head Personalized of Medicine and Companion Diagnostics at Sanofi. At Sanofi, he defined the personalized medicine...

2014-05-28 08:31:28

NEW YORK, May 28, 2014 /PRNewswire/ -- Exosome Diagnostics, a leading developer of non-invasive, biofluid-based molecular diagnostics, today announced that William J. Kelly has been appointed as its chief financial officer, effective May 27, 2014. Mr. Kelly, 43, has over 20 years of financial management experience, including the past 13 years leading growing, international, publicly traded life science companies. For the past six years, Mr. Kelly worked at RepliGen Corporation,...

2014-03-11 08:29:02

NEW YORK, March 11, 2014 /PRNewswire/ -- Exosome Diagnostics today announced the initial close of its Series B financing round with the raising of $27 million. Proceeds will be used to advance development of the Company's proprietary platform technology and commercial programs for non-invasive, fluid-based molecular diagnostics in oncology, neurodegenerative diseases and other clinical areas. Key Points: -- Co-leading the financing were new investors QIAGEN and Arcus Ventures --...

2014-01-13 04:20:54

GERMANTOWN, Maryland, and HILDEN, Germany, January 13, 2014 /PRNewswire/ -- - Expanding collaboration to develop FDA-regulated diagnostics based on exosomes to measure gene mutations targeted by new anti-cancer therapies - Non-invasive detection of biomarkers from blood reduces patient risk and advances access to the benefits of personalized medicine - Automated biofluid-based molecular diagnostics have significant potential to...

2014-01-13 04:20:53

-- Collaboration will focus on enabling detection of known cancer biomarkers in blood plasma NEW YORK, Jan. 13, 2014 /PRNewswire/ -- Exosome Diagnostics today announced an expansion of its strategic collaboration with QIAGEN to develop non-invasive molecular diagnostics for use in detecting and monitoring actionable genetic mutations in lung cancer patients. In contrast with current molecular diagnostics requiring tissue biopsy, the focus will be to enable detection of...

2013-12-13 23:04:48

New England Peptide (NEP), a Massachusetts based biotech manufacturer, and The Atlantic Cancer Research Institute (ACRI), a leading cancer research center in Atlantic Canada, have launched a new biotech company. Excipio Technologies Inc. has a mandate to commercialize the Vn96 peptide developed by both NEP and ACRI for the isolation of exosomes and extracellular microvesicles. Gardner, MA (PRWEB) December 13, 2013 Vn96 is a synthetic peptide that was designed to specifically stick to...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related